| Oxidative stress and Alzheimer’s disease: dietary polyphenols as potential therapeutic agents AS Darvesh, RT Carroll, A Bishayee, WJ Geldenhuys, CJ Van der Schyf Expert review of neurotherapeutics 10 (5), 729-745, 2010 | 271 | 2010 |
| Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells JA Gaasch, PR Lockman, WJ Geldenhuys, DD Allen, CJ Van der Schyf Neurochemical research 32, 1196-1208, 2007 | 256 | 2007 |
| Pharmacology and structure‐activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives WJ Geldenhuys, SF Malan, JR Bloomquist, AP Marchand, ... Medicinal research reviews 25 (1), 21-48, 2005 | 241 | 2005 |
| Curcumin and neurodegenerative diseases: a perspective AS Darvesh, RT Carroll, A Bishayee, NA Novotny, WJ Geldenhuys, ... Expert opinion on investigational drugs 21 (8), 1123-1140, 2012 | 215 | 2012 |
| Optimizing the use of open-source software applications in drug discovery WJ Geldenhuys, KE Gaasch, M Watson, DD Allen, CJ Van der Schyf Drug discovery today 11 (3-4), 127-132, 2006 | 180 | 2006 |
| 8-(3-Chlorostyryl) caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism JF Chen, S Steyn, R Staal, JP Petzer, K Xu, CJ Van der Schyf, ... Journal of Biological Chemistry 277 (39), 36040-36044, 2002 | 140 | 2002 |
| Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists JP Petzer, S Steyn, KP Castagnoli, JF Chen, MA Schwarzschild, ... Bioorganic & medicinal chemistry 11 (7), 1299-1310, 2003 | 131 | 2003 |
| Role of serotonin in Alzheimer’s disease: a new therapeutic target? WJ Geldenhuys, CJ Van der Schyf CNS drugs 25 (9), 765-781, 2011 | 129 | 2011 |
| In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery AS Darvesh, RT Carroll, WJ Geldenhuys, GA Gudelsky, J Klein, ... Expert opinion on drug discovery 6 (2), 109-127, 2011 | 114 | 2011 |
| The emergence of designed multiple ligands for neurodegenerative disorders WJ Geldenhuys, MBH Youdim, RT Carroll, CJ Van der Schyf Progress in neurobiology 94 (4), 347-359, 2011 | 112 | 2011 |
| Multifunctional drugs with different CNS targets for neuropsychiatric disorders CJ Van der Schyf, WJ Geldenhuys, MBH Youdim Journal of neurochemistry 99 (4), 1033-1048, 2006 | 111 | 2006 |
| The use of multi-target drugs in the treatment of neurodegenerative diseases CJ Van der Schyf Expert review of clinical pharmacology 4 (3), 293-298, 2011 | 106 | 2011 |
| Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs J Joubert, WJ Geldenhuys, CJ Van der Schyf, DW Oliver, HG Kruger, ... ChemMedChem 7 (3), 375-384, 2012 | 105 | 2012 |
| Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridinyl derivatives H Inoue, K Castagnoli, C Van der Schyf, S Mabic, K Igarashi, ... Journal of pharmacology and experimental therapeutics 291 (2), 856-864, 1999 | 101 | 1999 |
| NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia A Mdzinarishvili, WJ Geldenhuys, TJ Abbruscato, U Bickel, J Klein, ... Neuroscience letters 383 (1-2), 49-53, 2005 | 100 | 2005 |
| Dual-target–directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson's disease JP Petzer, N Castagnoli Jr, MA Schwarzschild, JF Chen, CJ Van der Schyf Neurotherapeutics 6 (1), 141-151, 2009 | 95 | 2009 |
| Nicotine exacerbates brain edema during in vitro and in vivo focal ischemic conditions JR Paulson, T Yang, PK Selvaraj, A Mdzinarishvili, CJ Van der Schyf, ... Journal of pharmacology and experimental therapeutics 332 (2), 371-379, 2010 | 90 | 2010 |
| Synthesis and biological evaluation of pentacyclo [5.4. 0.02, 6.03, 10.05, 9] undecane derivatives as potential therapeutic agents in Parkinson's disease WJ Geldenhuys, SF Malan, T Murugesan, CJ Van der Schyf, ... Bioorganic & medicinal chemistry 12 (7), 1799-1806, 2004 | 86 | 2004 |
| The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease WJ Geldenhuys, CJ Van der Schyf Expert review of neurotherapeutics 9 (7), 1073-1085, 2009 | 83 | 2009 |
| Multifunctional neuroprotective drugs targeting monoamine oxidase inhibition, iron chelation, adenosine receptors, and cholinergic and glutamatergic action for … CJ Van der Schyf, S Gal, WJ Geldenhuys, MBH Youdim Expert opinion on investigational drugs 15 (8), 873-886, 2006 | 82 | 2006 |
Werner GeldenhuysWest Virginia University在 hsc.wvu.edu 的电子邮件经过验证
